WO2007008154A1 - Method for evaluating the effects of smoke on bronchioles - Google Patents
Method for evaluating the effects of smoke on bronchioles Download PDFInfo
- Publication number
- WO2007008154A1 WO2007008154A1 PCT/SE2006/000862 SE2006000862W WO2007008154A1 WO 2007008154 A1 WO2007008154 A1 WO 2007008154A1 SE 2006000862 W SE2006000862 W SE 2006000862W WO 2007008154 A1 WO2007008154 A1 WO 2007008154A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bronchioles
- vessels
- smoke
- effects
- bioactive agent
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- TITLE Method for evaluating the effects of smoke on bronchioles
- the invention relates to a method to evaluate the effects of the lipid soluble part obtained from smoke on bronchioles as well as identifying bioactive agents, which is capable of reducing the effects of smoke on smooth muscle cells in blood vessels or bronchioles.
- Cigarette smoking has since long been recognized as a strong risk factor that is linked with high incidence of atherosclerosis, acting in concert with hyperlipidemia and hypertension. Stroke, myocardial infarction and claudication are common among cigarette smokers (Wyngaarden & & Smith. Cecil Textbook of Medicine, 1-2404 (W.B. Saunders company, Philadelphia, 1988).
- the direct medical cost of cardiovascular disease is enormous in the Western world and smoking has been found to cause 5 million premature deaths per year worldwide, the majority of these are interestingly due to cardiovascular events (Lightwood. The economics of smoking and cardiovascular disease, Prog Cardiovasc Dis 46, 39-78 (2003).
- the method can also be used for the screening for agents that can prevent the changes that tobacco products induce in smooth muscle cells of blood vessels or airways as well as using the method to determine the expression of receptor regulation, which may be changed due to smoking, i.e., it is possible to use the method as a diagnostic method
- the invention relates to a method of evaluating the effects of the lipid soluble part obtained from smoke on dissected bronchioles, such as arterial or airway smooth muscle cells as well as identifying bioactive agents, which are capable of reducing the effects of smoke on vessels or the bronchioles.
- the invention relates to a method of evaluating the effects of the lipid soluble tobacco smoke particles on the smooth muscle cells in blood vessels or the bronchioles comprising the steps of; providing dissected bronchioles or vessels from an animal, exposing said dissected bronchioles or vessels to lipid soluble smoke particles, inducing upregulation of one or more receptors mediating tone prior to dissecting said bronchioles or vessels, immersing said dissected bronchioles or vessels in a medium and applying a tension on said bronchioles or vessels, determining the contractile response of said dissected bronchioles or vessels and evaluating the effects of smoke on smooth muscle cells in blood vessels or bronchioles.
- the invention in a second aspect relates to a method of evaluating the effects of tobacco smoke on the smooth muscle cells in blood vessels or the bronchioles comprising the steps of; providing dissected bronchioles or vessels from an animal, exposing said dissected bronchioles or vessels to lipid soluble smoke particles, inducing upregulation of one or more receptors mediating tone prior to dissecting said bronchioles or vessels, immersing said dissected bronchioles or vessels in a medium and applying a tension on said bronchioles or vessels, adding a bioactive agent, determining the contractile response of said dissected bronchioles or vessels and evaluating the effects of smoke on smooth muscle cells in blood vessels or bronchioles and obtaining a bioactive agent.
- the invention relates to a bioactive agent, which has been obtained by the above mentioned method as well as the use of said bioactive agent for the treatment of a disorder involving constriction of vessels or bronchioles such as after chronic obstructive lung disease or asthma bronchioles.
- lipid soluble smoke particles are intended to mean the fraction obtained in example 1.
- bioactive agent is intended to mean an agent being capable of acting as a protein kinase inhibitor being capable of normalising vascular tone by decreasing vasoconstriction or increasing vasodilatation of blood vessels, such as in arteries after ischemic brain injury.
- the term "medium” is intended to mean a solution, in which receptors of dissected arteries or bronchioles may be upregulating.
- receptors are endothelin, such A 1 and A 2 , angiotensin, such as AT 1 and AT 2 , serotonin, such as 5HT 1B an( i bradykinin, such as B 1 and B 2.
- physiological solutions will be obvious for a person skilled in the art. Examples are modified KREB 's, DMEM, fysiological NaCl, phosphate buffer etc
- treatment means that by inhibiting the signal resulting in transcription and translation, the receptor upregulation will be prevented and, hence, e.g. the sequel leading to penumbral zone damage and neuronal loss will be revoked.
- upregulation is intended to mean that receptors in the blood vessels and in the airways are changed in phenotype and/or increased in number, which will lead to deleterious effects on circulation and pulmonary function.
- bronchioles is intended to mean the airways after trachea.
- the present invention relates to the area of evaluating the effects of smoke on the smooth muscle cells in blood vessels or the bronchioles and thereby obtain knowledge about which of the particles in smoke are responsible for certain effects.
- the lipid soluble smoke particles may be from different tobacco products, such as conventional cigarettes or cigars. Particles which then may be removed from the tobacco and thereby a healthier tobacco may be obtained, which has less negative effects on the human being consuming the tobacco. It has surprisingly been found that tobacco smoke upregulate at least the endothelin receptors in arterial and bronchial smooth muscle cells (SMC).
- SMC arterial and bronchial smooth muscle cells
- the method may also be used to identify new bioactive agents, which can be use to treat disorders involving the bronchioles or the vessels as well as to determine expression of receptors, which becomes upregulated by lipid soluble smoke particles and thereby use the method to determine the degree of the disorder or disease caused by the lipid soluble smoke particles.
- constriction and/or dilatation may be induced in parallel or in sequence with upregulation of one or more receptors such as the endothelin receptors.
- the inventors have surprisingly found that blood vessels of tissue subjected to ischemia both in vivo and in vitro, such as the basilar artery and the middle cerebral artery, undergoes phenotypic changes so that the vasoconstrictor receptor population is upregulated, which result in excessive arterial constriction, and that for example the endothelin, the 5-hydroxytryptamine and angiotensin receptors are among those becoming upregulated.
- the same effects, albeit much stronger are seen by the use of tobacco lipid soluble smoke particles.
- the method can be used to understand the molecular mechanism involved in the upregulation of e.g., endothelin receptors; this process is involved in vascular and pulmonary disease. From this it is then possible to identify bioactive agents, which can be used to treat smoke induced diseases.
- the bioactive agent may act as a protein kinase inhibitor.
- the arterial or airway SMCs can be obtained from an animal such as rat, mouse, guinea-pig, dog, cat, horse or a synthetic version thereof.
- the SMCs may be obtained by the use of the technique disclosed by Adner et al., Plasticity of contractile endothelin-B receptors in human arteries after organ culture. Br J Pharmacol 119, 1159-66 (1996) and airway such as in Granstr ⁇ m et al., Upregulation of endothelin receptor function of mRNA expression in airway smooth muscle cells following sephadex-induced airway inflammation. Basic&Clinical Pharmacol Toxicol. 2004;95:43-48.
- the isolated arteries or bronchioles are then exposed to tobacco smoke or tobacco lipid soluble smoke particles, which have been extracted from said smoke, such as water soluble particles or lipid soluble particles.
- tobacco smoke or tobacco lipid soluble smoke particles which have been extracted from said smoke, such as water soluble particles or lipid soluble particles.
- tobacco smoke or tobacco lipid soluble smoke particles are Example 1.
- the bronchioles may be dissected into smaller segments or discs either prior to be exposed to the tobacco lipid soluble smoke particles or after.
- the bronchioles will during the exposure to the lipid soluble smoke particles either upregulate the endothelin receptors or the endothelin receptors may remain more or less active.
- tobacco which has been evaluate have activated the endothelin receptors and the conclusion is that if the particles which upregulate the endothelin receptors are removed from the tobacco a healthier tobacco may be obtained or the tissues will not be prone to diseases. Therefore the invented method is important and should be a useful tool in the development of new tobacco.
- the method can also be used for the screening for agents that can prevent the changes that tobacco products induce in smooth muscle cells of blood vessels in airways as well as using the method to determine the expression of receptor regulation, which may be changed due to smoking, i.e., it is possible to use the method as a diagnostic method
- DSP DMSO-soluble smoke particle
- the DMSO-soluble smoke particle (DSP) preparations were analyzed by gas chromatograph-flame ionisation detection (GC-FID, Agilent 6890N, USA) with a 0.23 mm x 15 mm x 0.25 m DB-5MS capillary column (Agilent, USA).
- GC-FID gas chromatograph-flame ionisation detection
- the GC-FID temperatures were programmed from 5O 0 C, increased with 5°C/min to 280 0 C and remained for 3 min.
- the concentration of nicotine in DSP was calculated according to standard nicotine peak value and area. After DSP preparations have been analyzed by the gas chromatograph, they were diluted by DMSO to standard nicotine content (0.11 mg/L) and used for organ culture experiments.
- Sprague-Dawley rats 250-300 g, male or female were euthanized with CO2, the head cut off and exsanguinated.
- the superior mesenteric artery was removed gently, immersed in cold oxygenated buffer solution (in mM: NaCl 119, NaHCO3 15, KCl 4.6, MgC12 1.2, NaH2PO4 1.2, CaC12 1.5, glucose 5.5, pH 7.4) and dissected free of adhering tissue under a light microscope.
- Human middle cerebral arteries MCA
- the arteries were collected from three men and used for organ culture between 4 to 6 hrs after death due to a traffic accident.
- the experimental protocol for using rat and human arteries was approved by local Ethic's Committee of Shaanxi province (China).
- the bronchioles are mounted on two wires (Myograph, J.P. Trading, Denmark) submerged in a temperature controlled buffer solution (37°C) of the following composition (mM) NaCl 119, NaHCO 3 15, KCl 4.6, MgCl 2 1.2, NaH 2 PO 4 1.2, CaCl 2 1.5 and glucose 5.5.
- the buffer is continuously aerated with oxygen enriched with 5% CO 2 resulting in a pH of 7.4.
- Vessel segments three samples in each group, were placed on Tissue TEK (Gibco), frozen and subsequently sectioned into 8 ⁇ M thick slices.
- the primary antibodies used were rabbit antihuman ET B (IBL, 16207), diluted 1 :400, goat anti human ET A (Santa Cruz Biotechnologies, sc-2 1194), diluted 1 : 100, mouse anti rat smooth muscle actin (Serotec, MCA 1 905T) diluted 1 :100 and mouse anti rat CD3 1 (Serotec, MCA1746), diluted 1 :200. All dilutions were done in PBS with 10% fetal calf serum.
- the secondary antibodies used were donkey-anti-mouse CyTM5 conjugated (Jackson ImmunoResearch, 715- 175-150) 1 :100, donkey-anti-rabbit CyTM3 conjugated (Jacksonl mmunoResearch, 711-165-152) 1 :100 in PBS with 10% fetal calf serum. The antibodies were then detected at the appropriate wavelength in a confocal microscope (Zeiss, USA). As control only secondary antibodies were used. The absolute fluorescence were investigated with Image J (http://rsb.info.nih.gov/ij) and background fluorescence subtracted. The measurement was done where there was positive staining for smooth muscle actin, hence in the muscle portion of the vessel. The values obtained were mean fluorescence in the area selected.
- protease- and phosphatase inhibitors 10 mM Tris pH 7.4, 50 mM ⁇ - Glycerophosphate, 100 ⁇ M Na 3 VO 4 , 0.5% Deoxycholate, 1 mM EGTA, 1 mM EDTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 1% Triton X-IOO, 1 mM DTT, 20 ⁇ M Pepstatin, 20 ⁇ M Leupeptin, 0.1 U/ml Aprotinin, 1 nM Calyculin and 1 mM PMSF).
- protease- and phosphatase inhibitors 10 mM Tris pH 7.4, 50 mM ⁇ - Glycerophosphate, 100 ⁇ M Na 3 VO 4 , 0.5% Deoxycholate, 1 mM EGTA, 1 mM EDTA, 1 mM NaF, 20 mM Na 4 P 2 O 7 , 1% Triton X-IOO,
- Total protein concentration was determined using a BioRad DC kit (Hercules, CA, USA) and a Genesys 6 spectrophotometer (Thermo, Waltham, MA, U.S.A.). 45 ⁇ g total protein was loaded per lane on a 10% SDS-PAGE gel and blotted onto a Hybond PVDF membrane for 30 min at 1.5 mA/cm 2 . Subsequently the membrane was blocked in 5% non-fat milk for 1 hour at room temperature (RT) and incubated with primary antibody over-night at 4 0 C and with secondary antibody (Pierce, Rockford, IL, U.S.A.) for 1 hour at RT.
- RT room temperature
- the membranes were developed using the Supersignal Dura kit (Pierce, Rockford, IL, U.S.A.) and visualized using a Fujifilm LAS-1000 Luminiscent Image Analyzer (Stamford, CT, U.S.A.).
- pAkts ER.473 , pJNK, phospho-p38, Cell Signaling Technology, Beverly, MA, U.S.A.
- pELKl, ⁇ PKC ⁇ SE R645, ⁇ PKC ⁇ SE R729 Biosource, Camarillo, CA, U.S.A.
- ET A and ET B Chemicon, Temecula, CA, U.S.A.
- pERK Promega, Madison, WI, U.S.A. was used at 1:2500.
- Circular segments including two cartilage segments were cut from trachea and bronchi. Each segment was denuded of its epithelium with a metal tread of 1 mm in diameter and a surface as a fmegraded file to avoid confounding dilatory effects (Hadj-Kaddour et al, 1996).
- Concentration-response experiments were conducted in three parts: First, the endothelin receptors in trachea where characterised using endothelin-1 and S6c in the absence or the presence of the endothelin ET A -antagonist FR 139317 (lO ⁇ M), the endothelin ET B -antagonist BQ 788 (lO ⁇ M), or in the presence of a combination of the two antagonists or the combined ET receptor antagonist bosentan (lO ⁇ M). Second, after the eosinofilic inflammation had been established (24h), the effect of endothelin-1 and S6 was studied at two levels of the rat airways, trachea and bronchus.
- Acetylcholine was added (1 mM) when maximum contraction was reached by the endothelin agonists. All segments could be used in this study, i.e. no segment was damaged through removal of epithelium or from the Sephadex induced inflammation. The airway epithelial cells were removed mechanically by wodden stick and the result controlled by histological investigation after the experiments (haematoxylin -eosin staining).
- Standard buffer solution NaCl 119, NaHCO 3 15, KCl 4.6, MgC12 1.2,
- PD98059, SB239063, SB408039, SB386023b and SB203580 were purchased from
- RNA samples of the lung were snap-frozen in liquid nitrogen immediately after acquisition and total cellular RNA was extracted using the TRIzol reagent (Gibco BRL) following the supplier's instructions. The resulting RNA pellet was finally washed with 70% ice-cold ethanol air-dried and redissolved in 10 ⁇ l diethyl- pyrocarbonate (DEPC)-treated water. The amount of RNA was determined by use of spectrophotometry (DU64 spectrophotometer; Beckman, Fullerton, CA, USA) considering a ratio of OD 260:280 > 1.6 as pure.
- spectrophotometry DU64 spectrophotometer; Beckman, Fullerton, CA, USA
- RT-PCR was carried out using the GeneAmp RNA PCR kit (Perkin-Elmer, Foster City, CA, USA) on a DNA Thermal cycler (Perkin-Elmer).
- Specific primers for the rat endothelin ET A - (generating a 264 basepair product) and endothelin ET B receptors (generating a 560 basepair product) were designed as follows: Endothelin ET A -receptor forward: 5 '-TACAAGGGCGAGCAGCACAGGA-3 ' reverse: 5 ' -CACAGGGCGAAGATGACAACCAA-S '
- Endothelin ET B -receptor forward 5 '- TGACGCCACCCACTAAGAC-3 ' reverse: 5 '-GACAGCCAGAACCACAGAGA-3 '
- RNA to cDNA The reverse transcription of total RNA to cDNA and subsequent PCR were carried out with the GeneAmp RNA PCR kit (Perkin Elmer, Foster City, USA) in a Perkin Elmer DNA Thermal Cycler.
- First strand cDNA was synthesised from 1 ⁇ g total RNA in a 20- ⁇ l reaction volume using random hexamers as primers. The reaction mixture was incubated at 25 0 C for 10 min, 42 0 C for 15 min, heated to 99 0 C for 5 min, and chilled to 5 0 C for 5 min. For each primer pair a 9- ⁇ l portion from the resultant cDNA was amplified by PCR in a final volume of 50 ⁇ l.
- the PCR was carried out with the following profile: 5 min at 95 0 C for 1 cycle, followed by 30 cycles of 1 min at 95 0 C, 1 min at 57 0 C and 30 sec at 72 0 C; final extension was done for 7 min at 72 0 C.
- a blank (water) was included in all experiments. Control experiments showed that 30 cycles were within the exponential phase of the PCR (not shown).
- the identity of the PCR products was verified by restriction analysis as follows: The endothelin ET A products were digested with SpH I (Boehringer Mannheim, Germany), generating three fragments of 27, 78 and 159 basepairs, respectively. The endothelin ET ⁇ -products were cleaved with Eco RV (Boehringer), generating two fragments of 106 and 454 basepairs respectively. The lung tissue was snap frozen in -8O 0 C after removal. Total cellular RNA was extracted using the FastRNATM Kit-GREEN and FastPrep® FP 120 Cell Disrupter (BIOlOl, Qbiogene, Carlsbad CA, USA) following the suppliers' instructions.
- RNA to cDNA was then redissolved in 10 ⁇ L diethyl-pyrocarbonate (DEPC)- treated water.
- DEPC diethyl-pyrocarbonate
- Reverse transcription of total RNA to cDNA was carried out using the GeneAmp RNA PCR kit (PE Applied Biosystems, Foster City, CA, USA) in a Perkin-Elmer DNA Thermal cycler.
- First strand cDNA was synthesized from 1 ⁇ g total RNA in a 20 ⁇ L reaction volume using random hexamers as primers. The reaction mixture was incubated at 25°C for 10 min, 42°C for 15 min, heated to 99°C for 5 min and chilled to 5 °C for 5 min.
- Real-time PCR was performed in a GeneAmp 5700 Sequence Detection System (Perkin-Elmer, Applied Biosystems, Foster City, CA, USA) using the GeneAmp S YBR ® Green kit (Perkin-Elmer, Applied Biosystems Foster City, CA, USA) with the cDNA synthesized above as template in a 50 ⁇ L reaction volume. A no template control was included in all experiments.
- the GeneAmp 5700 Sequence Detection System monitors the growth of DNA in real-time using an optic and imaging system, via the binding of a fluorescent dye to double-stranded DNA. Specific primers for the rat ET A and ET B receptors were designed as follows:
- Elongation factor- 1 (EF-I) mRNA was used as a reference, since it is the product of a housekeeping gene, continuously expressed to a constant amount in cells.
- the EF-I Elongation factor- 1
- the real-time PCR was carried out with the following profile: 50°C for 2 min, 95°C for 10 min, 95°C for 15 sec times 40 and 60°C for 1 min.
- E is the amplification efficiency with the optimal value of 1.
- PCR Oligonucleotides and reagents for the PCR assay were purchased from Perkin- Elmer, Applied Biosystems Foster City, CA, USA.
- PCR experiments were performed on n sephadex treated rats and n saline treated rats.
- Statistical analysis was performed, where p ⁇ 0.05 was considered significant.
- RNA to cDNA was carried out using the GeneAmp RNA PCR kit (PE Applied Biosystems, Foster City, CA, USA) in a Perkin-Elmer DNA Thermal cycler. First strand cDNA was synthesized from total RNA in a 40 ⁇ L reaction volume using random hexamers as primers. The reaction mixture was incubated at 25 0 C for 10 min, heated to 42 0 C for 15 min, further heated to 99 0 C for 5 min and chilled to 5°C for 5 min.
- EPC diethyl-pyrocarbonate
- Real-time PCR was performed in a GeneAmp 5700 Sequence Detection System using the GeneAmp SYBR ® Green kit (Perkin- Elmer, Applied Biosystems Foster City, CA, USA) with the cDNA synthesized above as template in a 50 ⁇ L reaction volume. A no template control was included in all experiments.
- the GeneAmp 5700 Sequence Detection System monitored the growth of DNA in real-time using an optic and imaging system, via the binding of a fluorescent dye to double-stranded DNA.
- Specific primers for the ATi and AT 2 receptors, ACE and NF -KB were designed as follows:
- AT 1 receptor forward 5 ' -GGATGGTTCTCAGAGAGTACAT-S ' reverse: 5'-CCTGCCCTCTTGTACCTGTTG -3 '
- AT 2 receptor forward 5 ' -TCTGTTAGTGGGATGCATGTAATCA-S ' reverse: 5 '-TGTGGGCCTCCAAACCATT-S '
- ACE forward 5'-CCCGGAAATACGAAGAATTGC-S' reverse: 5 '-GGCTCTCCCCACCTTGTCTC-3 '
- NF-KB forward 5 '-GAGAGCCAGTAGCACGCATG-3 ' reverse: 5 '-CCTGGGTTCGTGGAATGAGT-S '
- Elongation factor- 1 (EF-I) and glyceraldehyde 3 -phosphate dehydrogenase (GAPDH) mRNA were used as endogenous standards, and the primers were designed as follows:
- the real-time PCR was carried out with the following profile: 50 0 C for 2 min, followed by 40 cycles with 95°C for 15 sec and 60 0 C for 1 min.
- C T - values we refer to the number of PCR cycles performed per gene product in one sample at a specific point of time. Data are expressed as mean values + SEM. Statistical analyses were performed with unpaired Students' t-test and P ⁇ 0.05 was considered significant.
- the tissue used for Western blots was incubated initially in 500 DL Laemmli solution and homogenized with a polytron (IKA labortechnik, Germany). The lysates were centrifuged at 5000 X g for 5 minutes at 4° C and the supernatant transferred to new tubes. Further Laemmli solution was added to obtain a concentration of approximately 75 mg tissue/mL. The lysates were stored at -20° C until use.
- the proteins were heated to 97-100° C for 3-5 minutes to denature most proteins. Equal amounts of the boiled supernatant fraction were loaded onto a 10 % polyacrylamid gel, separated by electrophoresis (Mini-protean 3, Bio-Rad, CA) and then transferred to semi-blot PVDF membranes (Bio-Rad) by semidry blotting (Trans-blot SD, Bio-Rad). The Western blots were blocked with a solution of 5 % skim milk in TBS-T (0.1 % Tween-20 in TBS) and incubated overnight at 4° C in TBS-T containing skim milk and an appropriate dilution of polyclonal antibodies.
- the membranes were washed in TBS-T, incubated for 90 minutes with anti-rabbit IgG horseradish peroxidase-labelled secondary antibody (1:50 000). After further washing, the PVDF membranes were subjected to SuperSignal West and the chemiluminescence was detected by a Luminiscent Image Analyzer (Fujifilm Science Imaging systems, Japan). In the p38 and Akt-protein kinase gels, the cell extract from the rat bronchioles were applied to the gel as a positive control. For further details on the methodology see (Frodin et al., 2002).
- Goat polyclonal antibody was used to detect ERK1/2 (Santa Cruz Biotechnology, USA), while a polyclonal rabbit antibody (Promega, USA) was used to detect phospho-ERKl/2 kinase.
- Rabbit polyclonal antibodies (Cell Signaling Technology, USA) were used to detect p38 MAP kinase, phospho-p38 MAP kinase (Thrl80/Tyrl82), Akt protein kinase, phospho-Akt protein kinase (Thr308) and phospho-Akt (Ser473).
- DSP contains 0.11 mg/L of nicotine and thus this concentration was used to examine if nicotine was the key substance in the DSP-induced reduction of vasodilatation. Compared to nicotine, DSP had a significantly stronger effect in reducing the ACh-induced dilatation. However, in comparison with DMSO (control) nicotine did not produce any significant reduction of vasodilatation (Fig.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002609597A CA2609597A1 (en) | 2005-07-08 | 2006-07-07 | Method for evaluating the effects of smoke on bronchioles |
JP2008520219A JP2009500032A (en) | 2005-07-08 | 2006-07-07 | A method to assess the effect of smoke on bronchioles |
AU2006267162A AU2006267162A1 (en) | 2005-07-08 | 2006-07-07 | Method for evaluating the effects of smoke on bronchioles |
EP06758046A EP1902314A1 (en) | 2005-07-08 | 2006-07-07 | Method for evaluating the effects of smoke on bronchioles |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501612 | 2005-07-08 | ||
SE0501612-6 | 2005-07-08 | ||
US70581405P | 2005-08-05 | 2005-08-05 | |
US60/705814 | 2005-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007008154A1 true WO2007008154A1 (en) | 2007-01-18 |
Family
ID=37637413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2006/000862 WO2007008154A1 (en) | 2005-07-08 | 2006-07-07 | Method for evaluating the effects of smoke on bronchioles |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1902314A1 (en) |
JP (1) | JP2009500032A (en) |
AU (1) | AU2006267162A1 (en) |
CA (1) | CA2609597A1 (en) |
WO (1) | WO2007008154A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102012415A (en) * | 2010-04-28 | 2011-04-13 | 范维林 | Material combustion smoke toxicity experiment device |
USD854958S1 (en) | 2017-02-27 | 2019-07-30 | Amazon Technologies, Inc. | Wireless entrance communication device |
USD856838S1 (en) | 2014-07-18 | 2019-08-20 | Amazon Technologies, Inc. | Wireless entrance communication device |
USD866379S1 (en) | 2017-02-27 | 2019-11-12 | Amazon Technologies, Inc. | Wireless entrance communication device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04145085A (en) * | 1990-09-25 | 1992-05-19 | Asahi Chem Ind Co Ltd | Gamma-lactam ring derivative of staurosporin and ammonium salt thereof |
-
2006
- 2006-07-07 AU AU2006267162A patent/AU2006267162A1/en not_active Abandoned
- 2006-07-07 CA CA002609597A patent/CA2609597A1/en not_active Abandoned
- 2006-07-07 JP JP2008520219A patent/JP2009500032A/en active Pending
- 2006-07-07 WO PCT/SE2006/000862 patent/WO2007008154A1/en active Application Filing
- 2006-07-07 EP EP06758046A patent/EP1902314A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04145085A (en) * | 1990-09-25 | 1992-05-19 | Asahi Chem Ind Co Ltd | Gamma-lactam ring derivative of staurosporin and ammonium salt thereof |
Non-Patent Citations (5)
Title |
---|
DATABASE WPI Week 199226, Derwent World Patents Index; Class B02, AN 1992-214293, XP003003237 * |
HIROKI J. ET AL.: "Divergent effects of estrogen and nitocine on Rho-kinase expression in human coronary vascular smooth muscle cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, no. 326, 2005, pages 154 - 159, XP004672562 * |
RISSE P.-A. ET AL.: "Protease-activated receptor 2 in regulating of bronchomotor tone: Effect of tobacco smoking", LIFE SCIENCES, no. 75, 2004, pages 991 - 1002, XP003003235 * |
SANG-DO LEE ET AL.: "Cigarette smoke extract induces endothelin-1 via protein kinase C in pulmonary artery endothelial cells", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 281, 2001, pages 403 - 411, XP003003234 * |
UDDMAN E. ET AL.: "Protein kinase C inhibitors decrease endothelin ETB receptor mRNA expression and contraction during organ culture of rat mesenteric artery", EUROPEAN JOURNAL OF PHARMACOLOGY, no. 452, 2002, pages 215 - 222, XP003003236 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102012415A (en) * | 2010-04-28 | 2011-04-13 | 范维林 | Material combustion smoke toxicity experiment device |
CN102012415B (en) * | 2010-04-28 | 2014-06-18 | 范维林 | Material combustion smoke toxicity experiment device |
USD856838S1 (en) | 2014-07-18 | 2019-08-20 | Amazon Technologies, Inc. | Wireless entrance communication device |
USD854958S1 (en) | 2017-02-27 | 2019-07-30 | Amazon Technologies, Inc. | Wireless entrance communication device |
USD866379S1 (en) | 2017-02-27 | 2019-11-12 | Amazon Technologies, Inc. | Wireless entrance communication device |
USD866380S1 (en) | 2017-02-27 | 2019-11-12 | Amazon Technologies, Inc. | Wireless entrance communication device |
Also Published As
Publication number | Publication date |
---|---|
CA2609597A1 (en) | 2007-01-18 |
AU2006267162A1 (en) | 2007-01-18 |
EP1902314A1 (en) | 2008-03-26 |
JP2009500032A (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marinucci et al. | Nicotine induces apoptosis in human osteoblasts via a novel mechanism driven by H2O2 and entailing Glyoxalase 1-dependent MG-H1 accumulation leading to TG2-mediated NF-kB desensitization: Implication for smokers-related osteoporosis | |
Hashimoto et al. | Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A-and phosphatidylinositol 3-kinase/Akt-dependent mechanism | |
Carnevali et al. | Cigarette smoke extract inhibits fibroblast-mediated collagen gel contraction | |
Gairola et al. | Sidestream cigarette smoke accelerates atherogenesis in apolipoprotein E−/− mice | |
Trabucco et al. | Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage | |
Merigo et al. | α-Gustducin immunoreactivity in the airways | |
Habiel et al. | Divergent roles for clusterin in lung injury and repair | |
Karlsson et al. | Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn–effects of peripheral nerve lesion and inflammation | |
Xu et al. | Cigarette smoke extracts promote vascular smooth muscle cell proliferation and enhances contractile responses in the vasculature and airway | |
Wang et al. | Effects of chronic exposure to cigarette smoke on canonical transient receptor potential expression in rat pulmonary arterial smooth muscle | |
Sandhu et al. | Upregulation of contractile endothelin type B receptors by lipid-soluble cigarette smoking particles in rat cerebral arteries via activation of MAPK | |
EP1902314A1 (en) | Method for evaluating the effects of smoke on bronchioles | |
Milara et al. | Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries | |
Solari et al. | Expression of heme oxygenase-1 and endothelial nitric oxide synthase in the lung of newborns with congenital diaphragmatic hernia and persistent pulmonary hypertension | |
Zheng et al. | NF-kappaB signaling mediates vascular smooth muscle endothelin type B receptor expression in resistance arteries | |
Żychowska et al. | Increased serum level and high tissue immunoexpression of interleukin 17 in cutaneous lichen planus: a novel therapeutic target for recalcitrant cases? | |
Huang et al. | Lipid soluble smoke particles upregulate endothelin receptors in rat basilar artery | |
Jun et al. | Role of extracellular signal-regulated kinase 1/2 in cigarette smoke-induced mucus hypersecretion in a rat model | |
Gao et al. | Remote ischemic conditioning mediates cardio-protection after myocardial ischemia/reperfusion injury by reducing 4-HNE levels and regulating autophagy via the ALDH2/SIRT3/HIF1α signaling pathway | |
Patrignani et al. | Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study | |
Uddman et al. | Role of mitogen-activated protein kinases in endothelin ETB receptor up-regulation after organ culture of rat mesenteric artery | |
Cao et al. | The effects of MEK1/2 inhibition on cigarette smoke exposure-induced ET receptor upregulation in rat cerebral arteries | |
Granström et al. | Smoking particles enhance endothelin A and endothelin B receptor-mediated contractions by enhancing translation in rat bronchi | |
Le et al. | Secondhand smoke exposure impairs ion channel function and contractility of mesenteric arteries | |
López et al. | Stanniocalcin 2 regulates non-capacitative Ca2+ entry and aggregation in mouse platelets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680024948.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2609597 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006267162 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006267162 Country of ref document: AU Date of ref document: 20060707 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006267162 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2008520219 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 564930 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006758046 Country of ref document: EP |